CANCERCare
A PROGRAM OF EASTERN HEALTH
Cancer Care Program

Doctor's Order Sheet

Perjeta®(PERTuzumab) 420 mg - Herceptin®(trastuzumab) 6 mg/kg - Abraxane®(NAB-PACLitaxel) 100 Regimen: Post Cycle 1 (Part I)

Name:

HCN:

Date of Birth:

ARIA Protocol Name: PERT/Herceptin(trastuzumab)21 ABRAX100

Adult Chemotherapy - Medical Oncology

Metastatic Breast Cancer Therapy

CC1850 0056 06 2020

Allergies: ☐ **No Known**

Date: DD/MONTH/YYYY

Cycle_____ of _____ **Cycle Duration: 21 days**

Planned Administration Date: DD/MONTH/YYYY

Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** 1.5 X 10^9/L and platelets **greater than or equal to** 100 X 10^9/L, otherwise notify Medical Oncologist.
- LFTs and Bilirubin assessed.
- Creatinine clearance assessed.

PREMEDICATIONS:

☐ Other: _____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

CANCERCare
A PROGRAM OF EASTERN HEALTH
Cancer Care Program

Doctor's Order Sheet

Perjeta®(PERTuzumab) 420 mg - Herceptin®(trastuzumab) 6 mg/kg - Abraxane®(NAB-PACLitaxel) 100 Regimen: Post Cycle 1

(Part II)

Name:

HCN:

Date of Birth:

ARIA Protocol Name: PERT/Herceptin(trastuzumab)21 ABRAX100

Adult Chemotherapy - Medical Oncology

Metastatic Breast Cancer Therapy

CC1850 0056 06 2020

Weight: _____kg Height:_____cm Body Surface Area (BSA) = _____

CHEMOTHERAPY:

☐ **Perjeta® (PERTuzumab) 420 mg**

IV in 250 mL normal saline over 60 minutes on day 1

Cycle 3 and beyond can be administered over 30 minutes if no previous reaction.

☐ **Herceptin® (trastuzumab) 6 mg/kg** X Weight (kg) = _____ **mg**

IV in 250 mL normal saline over 60 minutes on day 1

Cycle 3 and beyond can be administered over 30 minutes if no previous adverse reaction.

☐ **Abraxane® (NAB-PACLitaxel) 100 mg/m²** X BSA =_____**mg**

☐Dose modification: **Abraxane® (NAB-PACLitaxel) 100 mg/m²** X BSA - _____% = _____**mg**

IV in Viaflex bag over 30 minutes on days 1 and 8

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.